{"id":"W2598322637","doi":"10.1200/jco.2015.33.15_suppl.tps5071","title":"A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Placebo; Androgen receptor; Internal medicine; Population; Cancer; Clinical endpoint; Chemotherapy; Oncology; Pharmacology; Urology; Randomized controlled trial; Androgen deprivation therapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002607415,0.002728032,0.003691399,0.0007863606,0.0008356825,0.00139978,0.001821502,0.002755191,0.01164614],"category_scores_gemma":[0.00255903,0.001179419,0.002063619,0.0005661654,0.001880249,0.001643892,0.000530552,0.003970285,0.002499904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008601783,"about_ca_system_score_gemma":0.002324622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001329766,"about_ca_topic_score_gemma":0.003504041,"domain_scores_codex":[0.9990849,0.0004851132,0.00004740913,0.0001663034,0.00007281873,0.000143438],"domain_scores_gemma":[0.9984069,0.0004225564,0.0003431158,0.0001382625,0.0001211369,0.0005679679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9784195,0.01185446,0.0002113267,0.0004084112,0.0003173445,0.00002374269,0.00003774525,0.0002007226,0.002151864,0.00007564382,0.0006230007,0.005676171],"study_design_scores_gemma":[0.9596288,0.03911006,0.0004389747,0.00001213882,0.0001056464,0.00001248942,0.000009584226,0.0001746351,0.0001554301,0.0000886268,0.0002548546,0.000008743415],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9562109,0.005072707,0.001626133,0.001329141,0.001692407,0.02587309,0.003161077,0.0005527654,0.004481671],"genre_scores_gemma":[0.9490162,0.003609741,0.004893215,0.003255584,0.001039711,0.02757958,0.002435657,0.00009203671,0.008078356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01164614,"threshold_uncertainty_score":0.03896028,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2629922469881669,"score_gpt":0.5399140988926265,"score_spread":0.2769218519044596,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}